Aptose Biosciences (TSE:APS) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Aptose Biosciences has launched the TUSCANY Phase 1/2 study to test a new triplet therapy for newly diagnosed acute myeloid leukemia (AML) patients. This innovative treatment combines tuspetinib with azacitidine and venetoclax, aiming to offer an effective frontline therapy for AML patients who cannot undergo intensive chemotherapy. The trial is being conducted across several sites in the United States, with potential to impact a broad range of AML cases.
For further insights into TSE:APS stock, check out TipRanks’ Stock Analysis page.
